Metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia frequently coexist, yet their causal relationship and underlying ...

Aside from known risk of muscle symptoms and diabetes, adverse events included abnormal liver transaminases, other liver function test abnormalities, urinary composition alteration, and edema. Statins ...

Following the frequent suspicions regarding the safety of cholesterol-lowering drugs in the pre-statin era,1 statins have been a recurrent object of various concerns and alarming news. For example, ...

A new study from researchers at Stanford University and Nvidia proposes a way for AI models to keep learning after deployment — without increasing inference costs. For enterprise agents that have to ...

Using human liver samples and a mouse model of cirrhosis, researchers identified epigenetic overactivation of the inflammatory PAF–PAF-R pathway in hepatic macrophages as a key driver of liver damage.

Researchers have recently created a blood test that can detect liver disease years before symptoms ever develop, helping pave the way for the diagnosis of diseases such as cirrhosis and liver cancer ...

Researchers in Sweden and Finland have created the CORE model, a simple blood test that predicts liver disease risk with striking accuracy. Unlike current methods, it works for the general population ...

A new study from Karolinska Institutet, published in the scientific journal The BMJ, shows how a simple blood analysis can predict the risk of developing severe liver disease. The method may already ...

Researchers identified microRNA-93 as a genetic driver of fatty liver disease and showed that vitamin B3 can effectively suppress it. This breakthrough suggests niacin could be repurposed as a ...

Toxic “forever chemicals” are altering human liver function at a fundamental level by triggering both fat accumulation and cancer-linked cell damage, a new study has found. Several of these compounds, ...

In patients with hepatocellular carcinoma (HCC) who received immunotherapy, median overall survival was 20.6 months in those with preserved liver function. Metabolic dysfunction-associated steatotic ...